Christopher Ellis Archives
VHVI offers latest therapies to treat atrial fibrillation
Sep. 9, 2021—Vanderbilt Heart and Vascular Institute continues to offer the latest in therapies to treat atrial fibrillation (AF or AFib), the most common cardiac arrhythmia.
Device to treat AFib may eliminate need for blood thinners
Mar. 18, 2021—Vanderbilt University Medical Center is participating in a trial for a device that could revolutionize the way patients are treated for atrial fibrillation (AF or AFib.)
Minimally invasive treatment option for AFib studied
Oct. 22, 2020—A minimally invasive procedure that combines ligation of the left atrial appendage (LAA) with hybrid epicardial-endocardial ablation is a feasible, safe and effective method of treating patients with longstanding atrial fibrillation (AF or AFib), according to a new Vanderbilt-led study.
New device may aid advanced heart failure patients
Sep. 17, 2020—Vanderbilt Heart and Vascular Institute (VHVI) has implanted its first V-Wave, an interatrial shunt device, as a part of a multi-center clinical trial.
Tiny pacemaker helps keep patient’s heart in rhythm
Mar. 12, 2020—In February, Martha Hawks became the Southeast’s first recipient of the Medtronic Micra AV, the latest version of the tiny pacemaker that Vanderbilt Heart and Vascular Institute began testing in a clinical trial in 2014. The FDA approved the latest device in January.
Device helps heart patients ditch blood thinners
Feb. 7, 2019—For the first time in 27 years, Jerry Flowers is looking at life without using blood thinners, thanks to a small device that was implanted in his heart in a clinical trial at Vanderbilt Heart and Vascular Institute (VHVI).
VUMC testing device to reduce stroke risk in arrhythmia patients
Feb. 9, 2017—Vanderbilt University Medical Center (VUMC) is the first in the state to enroll patients in a clinical trial testing the effectiveness of the newest implantable device used to reduce stroke risk in patients with non-valvular atrial fibrillation (AF), the most common form of arrhythmia.
Device helps curb atrial fibrillation patients’ stroke risk
Aug. 25, 2016—Peggy Tubb doesn’t recall her exact reaction when she was told she could stop taking blood thinners to treat atrial fibrillation (AF), but the news changed her life.
Vanderbilt Heart offers alternative to blood thinners for atrial fibrillation
Jun. 17, 2015—Vanderbilt Heart and Vascular Institute now offers patients with atrial fibrillation (AF) an alternative treatment to reduce their risk of stroke, potentially avoiding the long-term use of blood thinners such as warfarin.
Heart Institute testing world’s tiniest pacemaker
Sep. 18, 2014—Vanderbilt Heart and Vascular Institute is participating in a global clinical trial to test the safety and efficacy of the world’s smallest pacemaker.
‘Envelope’ reduces cardiac implant infections
Aug. 8, 2013—Vanderbilt Heart and Vascular Institute is the first in the United States to use a new fully resorbable “envelope” that encloses implantable cardiac devices, such as pacemakers and internal cardioverter defibrillators (ICDs), and helps prevent surgical site infections.
New technique eases stroke risk for atrial fibrillation patients
Aug. 1, 2013—People with the most common irregular heart rhythm known as atrial fibrillation (AF) are at greater risk for stroke due to the formation of clots in the left atrial appendage (LAA), a small pouch which empties blood into the left atrium.